Rare ovarian tumours. Other treatments for ovarian cancer
Aim: The description of rare malignant ovarian tumours and the most suitable treatments. Alternative therapies different from intravenous chemotherapy are also explained. Methods: Literature review and ongoing trial information have been used to elaborate this guide. Results: Each ovarian cancer typ...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-08-01
|
Series: | EJC Supplements |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1359634919300035 |
id |
doaj-a764f5469d874f9f91eacb7ad27ad2d7 |
---|---|
record_format |
Article |
spelling |
doaj-a764f5469d874f9f91eacb7ad27ad2d72020-11-25T03:17:33ZengElsevierEJC Supplements1359-63492020-08-011596103Rare ovarian tumours. Other treatments for ovarian cancerMarta Gil-Martin0Beatriz Pardo1Maria-Pilar Barretina-Ginesta2Medical Oncology Department, Catalan Institute of Oncology-IDIBELL, L'Hospitalet-Barcelona, Spain; Corresponding author:Medical Oncology Department, Catalan Institute of Oncology-IDIBELL, L'Hospitalet-Barcelona, SpainMedical Oncology Department, Catalan Institute of Oncology (ICO), Girona, Spain; Girona Biomedical Research Institute (IDIBGI), Department of Medical Sciences, Medical School University of Girona (UdG), SpainAim: The description of rare malignant ovarian tumours and the most suitable treatments. Alternative therapies different from intravenous chemotherapy are also explained. Methods: Literature review and ongoing trial information have been used to elaborate this guide. Results: Each ovarian cancer type must be identified and treated properly from diagnostic to surgery, adjuvant treatment and metastatic disease. Hormonotherapy can be useful as an alternative treatment, especially in low-grade ovarian cancer and endometrioid subtype. Tumour characterisation is appropriated for treatment selection when targeted therapy is indicated. MEK inhibitors, tyrosine-kinase inhibitors, EGFR inhibitors, therapies against integrins, antibody–drug conjugates and other strategies are described. Antiangiogenics, PARP inhibitors and immunotherapy are discussed in other parts of this publication. Conclusion: Different ovarian cancer types must receive the appropriated treatment. Alternative therapies may be evaluated beyond the standard therapy, frequently in a clinical trial, and an individualised molecular study may help to find the best treatment.http://www.sciencedirect.com/science/article/pii/S1359634919300035Rare malignant ovarian tumoursHormonotherapyTargeted therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Marta Gil-Martin Beatriz Pardo Maria-Pilar Barretina-Ginesta |
spellingShingle |
Marta Gil-Martin Beatriz Pardo Maria-Pilar Barretina-Ginesta Rare ovarian tumours. Other treatments for ovarian cancer EJC Supplements Rare malignant ovarian tumours Hormonotherapy Targeted therapy |
author_facet |
Marta Gil-Martin Beatriz Pardo Maria-Pilar Barretina-Ginesta |
author_sort |
Marta Gil-Martin |
title |
Rare ovarian tumours. Other treatments for ovarian cancer |
title_short |
Rare ovarian tumours. Other treatments for ovarian cancer |
title_full |
Rare ovarian tumours. Other treatments for ovarian cancer |
title_fullStr |
Rare ovarian tumours. Other treatments for ovarian cancer |
title_full_unstemmed |
Rare ovarian tumours. Other treatments for ovarian cancer |
title_sort |
rare ovarian tumours. other treatments for ovarian cancer |
publisher |
Elsevier |
series |
EJC Supplements |
issn |
1359-6349 |
publishDate |
2020-08-01 |
description |
Aim: The description of rare malignant ovarian tumours and the most suitable treatments. Alternative therapies different from intravenous chemotherapy are also explained. Methods: Literature review and ongoing trial information have been used to elaborate this guide. Results: Each ovarian cancer type must be identified and treated properly from diagnostic to surgery, adjuvant treatment and metastatic disease. Hormonotherapy can be useful as an alternative treatment, especially in low-grade ovarian cancer and endometrioid subtype. Tumour characterisation is appropriated for treatment selection when targeted therapy is indicated. MEK inhibitors, tyrosine-kinase inhibitors, EGFR inhibitors, therapies against integrins, antibody–drug conjugates and other strategies are described. Antiangiogenics, PARP inhibitors and immunotherapy are discussed in other parts of this publication. Conclusion: Different ovarian cancer types must receive the appropriated treatment. Alternative therapies may be evaluated beyond the standard therapy, frequently in a clinical trial, and an individualised molecular study may help to find the best treatment. |
topic |
Rare malignant ovarian tumours Hormonotherapy Targeted therapy |
url |
http://www.sciencedirect.com/science/article/pii/S1359634919300035 |
work_keys_str_mv |
AT martagilmartin rareovariantumoursothertreatmentsforovariancancer AT beatrizpardo rareovariantumoursothertreatmentsforovariancancer AT mariapilarbarretinaginesta rareovariantumoursothertreatmentsforovariancancer |
_version_ |
1724631505996611584 |